A US subsidiary of Chinese genome sequencing company BGI has filed a patent infringement counterclaim against Illumina.
The US Patent and Trademark Office (USPTO) has granted a new CRISPR-Cas9 patent to the University of California (UC), the University of Vienna and Emmanuelle Charpentier, marking the fifth consecutive week that the USPTO has approved a new patent in their CRISPR portfolio.
Taiwan-based Personal Genomics Taiwan has taken gene-sequencing rival Pacific Biosciences to court in the US, over alleged patent infringement.
UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.
The University of Columbia has hit Illumina with a patent infringement suit relating to next-generation DNA sequencing, just days after the pharmaceutical company had one of the university’s patents invalidated at the US Patent and Trial Appeal Board.
The world's ”largest genetics project” to tackle deadly diseases was launched yesterday, September 11, supported by funding from the UK government, charities and four pharmaceutical companies.
An alliance of companies that use gene-editing technologies has released a bioethical framework, as controversy over gene-editing continues.
The World Health Organization has launched a global registry to track research on human genome editing.
Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.
Tensions appear to be running high in the dispute between the Broad Institute of MIT and Harvard and the University of California, Berkeley (UC Berkeley) over which first invented the CRISPR gene-editing technology.